Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
What is the dosing of Taltz® (ixekizumab)?
Information on the dosing schedule of ixekizumab depending on the indication is provided below.
Table of Contents
Ixekizumab Dosage Regimen
Please note that this statement solely focuses on the posology of Ixekizumab. Please find further information, e.g. on indications, method of administration, concomitant medication etc. in the Taltz label information.1
Plaque Psoriasis
Plaque Psoriasis in adults
The recommended dose is
- 160 mg by subcutaneous injection (two 80 mg injections) at week 0,
- followed by 80 mg (one injection) at weeks 2, 4, 6, 8, 10, and 12,
- then maintenance dosing of 80 mg (one injection) every 4 weeks.1
Paediatric plaque psoriasis (age 6 years and above)
Efficacy and safety data is not available in children below the age of 6 years.1
Available data do not support a posology below a body weight of 25 kg.1
Children’s body weight |
Recommended starting dose (week 0) |
Recommended dose every 4 weeks (Q4W) thereafter |
Greater than 50 kg |
160 mg (two 80 mg injections) |
80 mg |
25 to 50 kg |
80 mg |
40 mg |
Pre-filled syringe
For children prescribed 80 mg, ixekizumab can be used directly from the prefilled syringe.1
For instructions on preparation of ixekizumab 40 mg, see section 6.6 of the Taltz Summary of Product Characteristics.1
- Doses less than 80 mg must be prepared by a healthcare professional.1
Ixekizumab is not recommended for use in children with a body weight below 25 kg.1
Paediatric body weights must be recorded and regularly re-checked prior to dosing.1
Pre-filled pen
Ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional using the commercial Taltz 80 mg/1 ml prefilled syringe.1
Use the Taltz 80 mg pre-filled pen only in those children that require a dose of 80 mg and do not require dose preparation.1
Ixekizumab is not recommended for use in children with a body weight below 25 kg. Paediatric body weights must be recorded and regularly re-checked prior to dosing.1
Psoriatic Arthritis
The recommended dose is
- 160 mg by subcutaneous injection (two 80 mg injections) at Week 0,
- followed by 80 mg (one injection) every 4 weeks thereafter.1
For psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis, the recommended dosing regimen is the same as for plaque psoriasis.1
Axial Spondyloarthritis (Radiographic and Non-radiographic)
The recommended dose is
- 160 mg (two 80 mg injections) by subcutaneous injection at Week 0,
- followed by 80 mg every 4 weeks.1
Special Populations
Elderly (≥ 65 years)
No dose adjustment is required in elderly patients (≥65 years).1
There is limited information in subjects aged ≥75 years.1
Renal or hepatic impairment
Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1
All indications - Response
For all indications (plaque psoriasis in adults and children, psoriatic arthritis, axial spondyloarthritis) consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment.1
- Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1
References
1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland
Date of Last Review: 01 May 2023